Lithium-induced hypercalcemia with normal parathyroid hormone: A case report. 2019

Charles Dorflinger, and Matthew Fuller

Long-term use of lithium is a known risk factor for hypercalcemia often due to involvement of the parathyroid gland. Because of this, lithium-induced hypercalcemia typically occurs simultaneously with abnormal parathyroid hormone concentrations. This case report describes a 54-year-old white male who has received lithium therapy intermittently for more than 10 years. During admission to an acute inpatient psychiatric unit, the patient experienced hypercalcemia with normal parathyroid hormone concentrations and no other discernible cause. Based on the Naranjo algorithm, lithium was determined to be the probable cause of hypercalcemia. Current literature suggests that lithium-induced hypercalcemia occurs secondary to hyperparathyroidism; however, this case may provide evidence of another, unidentified cause.

UI MeSH Term Description Entries

Related Publications

Charles Dorflinger, and Matthew Fuller
January 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
Charles Dorflinger, and Matthew Fuller
January 2001, Psychosomatics,
Charles Dorflinger, and Matthew Fuller
January 2011, Internal medicine (Tokyo, Japan),
Charles Dorflinger, and Matthew Fuller
May 2021, BMC endocrine disorders,
Charles Dorflinger, and Matthew Fuller
April 1983, The New England journal of medicine,
Charles Dorflinger, and Matthew Fuller
January 2021, BMC endocrine disorders,
Charles Dorflinger, and Matthew Fuller
January 2010, Primary care companion to the Journal of clinical psychiatry,
Charles Dorflinger, and Matthew Fuller
January 2009, Wiener klinische Wochenschrift,
Copied contents to your clipboard!